Loading...
NPI 1386240786 · Salt Lake City, UT · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Nomi Health Inc. is a clinical medical laboratory provider located in Salt Lake City, Utah. This profile covers 5 Medicare and 9 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Nomi Health Inc. |
| Address | 1141 E 3900 S Ste 150 |
| City | Salt Lake City |
| State | UT |
| ZIP | 84124 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 10, 2020 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $9.1M |
| Medicare | $108.9K |
NOMI HEALTH INC. is enumerated as a Clinical Medical Laboratory in SALT LAKE CITY, UT with its NPI registered on 2020-12-10 (~6 years ago). The NPI tenure combined with the high-volume COVID testing codes on file suggests rapid build-out of lab operations since enumeration.
The provider is heavily Medicaid-focused in scale: total Medicare revenue is $108.9K while total Medicaid revenue is $9.1M, indicating Medicaid receipts dominate overall billing. This is effectively a single-payer–weighted profile where Medicaid activity drives the business economics.
Medicaid revenue is extremely concentrated: the precomputed top 3 Medicaid codes account for 95.3% of this provider's total Medicaid revenue, led by U0003 ($4.3M, 47.3%), U0004 ($3.5M, 38.7%) and 87636 ($858K, 9.4%). Each of those codes ranks #1 in-state and the data labels for U0003 and 87636 are “extreme outlier,” signaling the provider is a dominant statewide supplier for high-throughput SARS-CoV-2 and multiplex respiratory testing.
Claims volume on the Medicaid side is extraordinarily large for COVID-related services (U0004 104.1K claims, U0003 98.3K claims, G2023 210.1K claims, U0005 190.2K claims), reinforcing that the operation is built for high specimen throughput and extensive specimen-collection activity. These claim counts, paired with #1 in-state ranks, indicate a centralized or regional lab serving broad Medicaid testing needs.
Medicare revenue is modest and highly concentrated: the precomputed top 3 Medicare codes account for 79.6% of this provider's total Medicare revenue, driven by G2023 ($33.1K, 30.3%), 87636 ($28K, 25.6%), and U0004 ($26K, 23.7%). Nationally the provider’s volumes for those codes are generally described as typical or unremarkable, though 87636 sits at the 96th national percentile, indicating above-average presence in multiplex PCR testing even outside the state.
The code mix (U0003, U0004, U0005, 87636, G2023/G2024) points to a service-line built around infectious agent detection using high-throughput nucleic acid amplification and multiplex assays plus large-scale specimen collection. The presence of U0005 (faster turnaround/high-throughput variant) and specimen-collection codes suggests operational emphasis on rapid processing and mass testing workflows.
Competitive implications: statewide the provider is a market leader for core COVID testing codes (multiple #1 in-state ranks and “extreme outlier” labels), which creates leverage for Medicaid contracting and referral volume. Conversely, the business is concentrated both by payer (Medicaid) and by a few codes, so revenue is sensitive to shifts in public-health testing demand or policy changes affecting those specific CPT/HCPCS codes.
Though Medicare receipts are small in absolute terms, the provider’s high national percentile for 87636 (96th) shows technical capability in multiplex influenza/COVID testing that could support expansion or diversification beyond current Medicaid-dominated volumes. The combination of recent enumeration (~6 years) and rapid Medicaid-scale growth suggests an operational model optimized for pandemic-era diagnostic throughput.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,440 | $20 | $33.1K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 200 | $140 | $28K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 350 | $70 | $26K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 490 | $30 | $12.2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 140 | $70 | $10.1K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
9 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 98,350 | $40 | $4.3M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 104,090 | $30 | $3.5M |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 17,870 | $50 | $858K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 210,080 | $1 | $210.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 190,180 | $1 | $190.2K |
| 87428 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient specimen for antigens of severe acute respiratory syndrome (SARS) coronavirus, such as SARS–CoV–2… | 920 | $30 | $22.9K |
| 0002A | N/A | 160 | $20 | $3.4K |
| 0001A | N/A | 110 | $20 | $1.8K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen… | 230 | $1 | $680 |
How this provider's Medicaid billing volume and revenue compare to other Utah providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Utah median
9 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1 | 10 | 70 | $30 | $407K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 20 | 270 | $40 | $334.7K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 1 | 20 | 70 | $50 | $71K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1 | 30 | 80 | $1 | $25.1K |
| 87428 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient specimen for antigens of severe acute respiratory syndrome (SARS) coronavirus, such as SARS–CoV–2… | 9 | 50 | 130 | $40 | $21K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1 | 30 | 220 | $1 | $16.8K |
| 0001A | N/A | 14 | 50 | 40 | $20 | $9K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen… | 2 | 10 | 2,570 | $1 | $8.6K |
| 0002A | N/A | 11 | 40 | 30 | $30 | $7.2K |
Other providers in the same ZIP code as Nomi Health Inc., ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.